Overview
- Jurors found Apple infringed U.S. Patent No. 10,433,776 covering low‑power pulse‑oximetry methods used in certain Apple Watch models.
- The verdict determined that Apple integrated the capabilities into more than 43 million devices and awarded $634 million in damages.
- The jury concluded some Apple Watch models qualify as a legal 'patient monitor,' a definition central to Masimo’s claims.
- Apple said most other Masimo assertions were ruled invalid, noted the patent expired in 2022, and confirmed it will appeal the decision.
- The ruling lands as related proceedings continue, including an ITC review of Apple’s 2025 redesign that shifts some processing to a paired iPhone after CBP initially cleared imports.